MorphoSys to Present New Data on Pelabresib at the 2022 European Hematology Association (EHA)
Current TAP Partner
BOSTON, MA, May 12, 2022 - MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced that new data on pelabresib will be presented during the 2022 European Hematology Association Hybrid Congress (EHA 2022) in Vienna, Austria, from June 9 – 12, 2022.
Highlights from the presentations at EHA 2022 include:
- An oral presentation of clinical data from the ongoing Phase 2 MANIFEST study investigating pelabresib in combination with ruxolitinib for the treatment of patients with myelofibrosis who had not previously been treated with a JAK inhibitor (JAK inhibitor-naive) and patients with suboptimal response to ruxolitinib treated with pelabresib in combination with ruxolitinib (Abstract S198)
- An oral presentation of translational research from the ongoing Phase 2 MANIFEST study that suggests pelabresib’s potential disease modifying effect in patients with myelofibrosis (Abstract S192)
- A poster presentation of data from a matching-adjusted indirect comparison (MAIC) analysis of pelabresib in combination with ruxolitinib from the ongoing, Phase 2 MANIFEST study versus ruxolitinib, fedratinib or momelotinib monotherapy in patients with intermediate or high-risk myelofibrosis (P1029)
- A poster presentation that outlines the design and inclusion criteria of the ongoing Phase 3 MANIFEST-2 study, which is exploring the effectiveness and safety of pelabresib in combination with ruxolitinib in JAK inhibitor-naive myelofibrosis patients (Abstract P1030)
EHA 2022 Accepted Abstracts
| Abstract Title | Abstract Number | Date/Time |
| ORAL BET inhibitor pelabresib (CPI-0610) combined with ruxolitinib in patients with myelofibrosis — JAK inhibitor-naive or with suboptimal response to ruxolitinib — preliminary data from the MANIFEST study |
S198 | Saturday, June 11, 2022 11:30 a.m. – 12:45 p.m. CEST / 5:30 a.m. – 6:45 a.m. EST |
| ORAL Single-cell RNA profiling of myelofibrosis patients reveals pelabresib-induced decrease of megakaryocytic progenitors and normalization of CD4+ T cells in peripheral blood |
S192 | Saturday, June 11, 2022 4:30 p.m. – 5:45 p.m. CEST / 10:30 a.m. – 11:45 a.m. EST |
| POSTER Matching-adjusted indirect comparison (MAIC) of pelabresib (CPI-0610) in combination with ruxolitinib vs. ruxolitinib or fedratinib monotherapy in patients with intermediate or high-risk myelofibrosis |
P1029 | Friday, June 10, 2022 4:30 p.m. – 5:45 p.m. CEST / 10:30 a.m. – 11:45 a.m. EST |
| POSTER MANIFEST-2, a global, Phase 3, randomized, double-blind, active-control study of pelabresib (CPI-0610) and ruxolitinib vs. placebo and ruxolitinib in JAK-inhibitor-naive myelofibrosis patients |
P1030 | Friday, June 10, 2022 4:30 p.m. – 5:45 p.m. CEST / 10:30 a.m. – 11:45 a.m. EST |